Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial

INTRODUCTION: Simplified, but effective, hyperphosphatemia treatments with novel mechanisms of action, tolerable safety profiles, and low pill burden are needed for patients undergoing hemodialysis. Tenapanor is a calcium (Ca)-free, nonmetal, nonpolymeric drug that reduces phosphate absorption by se...

Descripción completa

Detalles Bibliográficos
Autores principales: Inaba, Masaaki, Une, Yotaro, Ikejiri, Kazuaki, Kanda, Hironori, Fukagawa, Masafumi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820999/
https://www.ncbi.nlm.nih.gov/pubmed/35155857
http://dx.doi.org/10.1016/j.ekir.2021.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820999/
https://www.ncbi.nlm.nih.gov/pubmed/35155857
http://dx.doi.org/10.1016/j.ekir.2021.11.008

Ejemplares similares